243 related articles for article (PubMed ID: 37579735)
1. Adalimumab-Induced Paradoxical Psoriasis Treated with Biologics Targeting the IL-17/IL-23 Axis in Patients with Hidradenitis Suppurativa.
Tsiogka A; Liakou AI; Agiasofitou E; Gregoriou S; Stratigos A; Rigopoulos D; Kontochristopoulos G
Dermatology; 2023; 239(6):937-941. PubMed ID: 37579735
[TBL] [Abstract][Full Text] [Related]
2. Hidradenitis suppurativa (HS): An unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases.
Faivre C; Villani AP; Aubin F; Lipsker D; Bottaro M; Cohen JD; Durupt F; Jeudy G; Sbidian E; Toussirot E; Badot V; Barbarot S; Debarbieux S; Delaporte E; Goegebeur G; Morel J; Nassif A; Duru G; Jullien D;
J Am Acad Dermatol; 2016 Jun; 74(6):1153-9. PubMed ID: 26965410
[TBL] [Abstract][Full Text] [Related]
3. Paradoxical Hidradenitis Suppurativa in Patients Receiving TNF-α Inhibitors: Case Series, Systematic Review, and Case Meta-Analysis.
Salvador-Rodriguez L; Montero-Vílchez T; Arias-Santiago S; Molina-Leyva A
Dermatology; 2020; 236(4):307-313. PubMed ID: 32135533
[TBL] [Abstract][Full Text] [Related]
4. The anti-inflammatory potency of biologics targeting tumour necrosis factor-α, interleukin (IL)-17A, IL-12/23 and CD20 in hidradenitis suppurativa: an ex vivo study.
Vossen ARJV; Ardon CB; van der Zee HH; Lubberts E; Prens EP
Br J Dermatol; 2019 Aug; 181(2):314-323. PubMed ID: 30657173
[TBL] [Abstract][Full Text] [Related]
5. Observational case series on adalimumab-induced paradoxical hidradenitis suppurativa.
Delobeau M; Abdou A; Puzenat E; Deveza E; Biver-Dalle C; van de Laak A; Roche-Kubler B; Vuitton L; Koch S; Wendling D; Aubin F
J Dermatolog Treat; 2016; 27(3):251-3. PubMed ID: 26368546
[TBL] [Abstract][Full Text] [Related]
6. Paradoxical psoriasiform reactions during treatment with adalimumab for hidradenitis suppurativa: Real-life experience and therapeutic response to other biological drugs.
Burzi L; Repetto F; Ribero S; Mastorino L; Quaglino P; Dapavo P
Dermatol Ther; 2022 Dec; 35(12):e15866. PubMed ID: 36175129
[TBL] [Abstract][Full Text] [Related]
7. Paradoxical psoriasis induced by TNF-α blockade shows immunological features typical of the early phase of psoriasis development.
Fania L; Morelli M; Scarponi C; Mercurio L; Scopelliti F; Cattani C; Scaglione GL; Tonanzi T; Pilla MA; Pagnanelli G; Mazzanti C; Girolomoni G; Cavani A; Madonna S; Albanesi C
J Pathol Clin Res; 2020 Jan; 6(1):55-68. PubMed ID: 31577850
[TBL] [Abstract][Full Text] [Related]
8. Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.
Lovrić I; Brkić J; Ćorluka M; Čović M; Pejić J; Zeljko Penavić J
Acta Dermatovenerol Croat; 2021 Jul; 29(2):108-110. PubMed ID: 34477078
[TBL] [Abstract][Full Text] [Related]
9. Paradoxical Reactions: Anti-Tumor Necrosis Factor Alpha Agents, Ustekinumab, Secukinumab, Ixekizumab, and Others.
Puig L
Curr Probl Dermatol; 2018; 53():49-63. PubMed ID: 29131037
[TBL] [Abstract][Full Text] [Related]
10. The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study.
Rivera-Díaz R; Pozo T; Alfageme F; Díaz Ley B; Osorio GF; Chico R; Vilarrasa E; Silvente C; Ciudad Blanco C; Romaní J; Martorell A; Fernández P; Romero Ferreiro C; Molina Leyva A
Actas Dermosifiliogr; 2023 Oct; 114(9):755-762. PubMed ID: 37331620
[TBL] [Abstract][Full Text] [Related]
11. A safety review of biologic therapies for the management of hidradenitis suppurativa and unmet needs.
Holcomb ZE; Porter ML; Kimball AB
Expert Opin Drug Saf; 2021 Oct; 20(10):1147-1161. PubMed ID: 33910441
[TBL] [Abstract][Full Text] [Related]
12. Reply to 'Paradoxical hidradenitis suppurativa induced by adalimumab biosimilar successfully treated with guselkumab in a patient with psoriasis. Comment on "Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab"'.
López Sanz P; Guzmán Pérez M; Guerrero Ramírez C; Manso Córdoba S; Alfaro Martínez ME; Azaña Defez JM
Clin Exp Dermatol; 2023 Jul; 48(8):940-941. PubMed ID: 37098182
[No Abstract] [Full Text] [Related]
13. Secukinumab-induced paradoxical hidradenitis suppurativa.
Navarro-Triviño FJ; Sanchez-Parera R; Ruiz-Villaverde R
Dermatol Ther; 2020 Jan; 33(1):e13150. PubMed ID: 31670893
[TBL] [Abstract][Full Text] [Related]
14. Certolizumab pegol in the treatment of severe hidradenitis suppurativa after adalimumab failure: A real-life experience.
Esme P; Akoglu G; Dalkıran CD; Caliskan E
Dermatol Ther; 2022 Nov; 35(11):e15782. PubMed ID: 35996992
[TBL] [Abstract][Full Text] [Related]
15. The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study.
Rivera-Díaz R; Pozo T; Alfageme F; Díaz Ley B; Osorio GF; Chico R; Vilarrasa E; Silvente C; Ciudad Blanco C; Romaní J; Martorell A; Fernández P; Romero Ferreiro C; Molina Leyva A
Actas Dermosifiliogr; 2023 Oct; 114(9):T755-T762. PubMed ID: 37479135
[TBL] [Abstract][Full Text] [Related]
16. Drug Survival of Biologics in Patients With Hidradenitis Suppurativa.
Ring HC; Maul JT; Yao Y; Wu JJ; Thyssen JP; Thomsen SF; Egeberg A
JAMA Dermatol; 2022 Feb; 158(2):184-188. PubMed ID: 34851360
[TBL] [Abstract][Full Text] [Related]
17. Long-standing refractory hidradenitis suppurativa responded to a brodalumab monotherapy in a patient with psoriasis: A possible involvement of Th17 across the spectrum of both diseases.
Yoshida Y; Oyama N; Iino S; Shimizu C; Hasegawa M
J Dermatol; 2021 Jun; 48(6):916-920. PubMed ID: 33609416
[TBL] [Abstract][Full Text] [Related]
18. Paradoxical hidradenitis suppurativa induced by adalimumab biosimilar successfully treated with guselkumab in a patient with psoriasis. Comment on 'Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab'.
Martora F; Fabbrocini G; Marasca C; Battista T; Megna M
Clin Exp Dermatol; 2023 Jun; 48(6):701-703. PubMed ID: 36883596
[No Abstract] [Full Text] [Related]
19. The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review.
Sanchez IM; Sorenson E; Levin E; Liao W
Dermatol Ther (Heidelb); 2017 Dec; 7(4):425-446. PubMed ID: 29143230
[TBL] [Abstract][Full Text] [Related]
20. Biology of Interleukin-17 and Novel Therapies for Hidradenitis Suppurativa.
Sabat R; Gudjonsson JE; Brembilla NC; van Straalen KR; Wolk K
J Interferon Cytokine Res; 2023 Dec; 43(12):544-556. PubMed ID: 37824200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
